IL295471A - Anti-bcma therapy in autoimmune disorders - Google Patents

Anti-bcma therapy in autoimmune disorders

Info

Publication number
IL295471A
IL295471A IL295471A IL29547122A IL295471A IL 295471 A IL295471 A IL 295471A IL 295471 A IL295471 A IL 295471A IL 29547122 A IL29547122 A IL 29547122A IL 295471 A IL295471 A IL 295471A
Authority
IL
Israel
Prior art keywords
seq
antibody
bcma
region
amino acid
Prior art date
Application number
IL295471A
Other languages
English (en)
Hebrew (he)
Inventor
Mensah Kofi
Plenge Robert
Roy Sophie
Zaller Dennis
Dovey Jennifer
Saenz Steven
Henault Jill
Doykan Camille
Calvino Jenna
Jin Xi
Paquette Joseph
Original Assignee
Bristol Myers Squibb Co
Mensah Kofi
Plenge Robert
Roy Sophie
Zaller Dennis
Dovey Jennifer
Saenz Steven
Henault Jill
Doykan Camille
Calvino Jenna
Jin Xi
Paquette Joseph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Mensah Kofi, Plenge Robert, Roy Sophie, Zaller Dennis, Dovey Jennifer, Saenz Steven, Henault Jill, Doykan Camille, Calvino Jenna, Jin Xi, Paquette Joseph filed Critical Bristol Myers Squibb Co
Publication of IL295471A publication Critical patent/IL295471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL295471A 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders IL295471A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
IL295471A true IL295471A (en) 2022-10-01

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295471A IL295471A (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Country Status (11)

Country Link
US (1) US20240052064A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103224A4 (cg-RX-API-DMAC7.html)
JP (1) JP7783183B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220141306A (cg-RX-API-DMAC7.html)
CN (1) CN115551539A (cg-RX-API-DMAC7.html)
AU (1) AU2021221123A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169696A1 (cg-RX-API-DMAC7.html)
IL (1) IL295471A (cg-RX-API-DMAC7.html)
MX (1) MX2022009784A (cg-RX-API-DMAC7.html)
WO (1) WO2021163329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用
WO2026033437A1 (en) * 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026037514A1 (en) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992797A1 (en) * 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
MA49911A (fr) * 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b

Also Published As

Publication number Publication date
KR20220141306A (ko) 2022-10-19
JP7783183B2 (ja) 2025-12-09
MX2022009784A (es) 2022-09-09
BR112022014646A2 (pt) 2022-09-13
EP4103224A1 (en) 2022-12-21
EP4103224A4 (en) 2023-08-16
CA3169696A1 (en) 2021-08-19
AU2021221123A1 (en) 2022-10-06
CN115551539A (zh) 2022-12-30
WO2021163329A1 (en) 2021-08-19
US20240052064A1 (en) 2024-02-15
JP2023514224A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
JP7106594B2 (ja) Pd-l1に対するヒト抗体
JP6865324B2 (ja) 抗cd3抗体、cd3及びcd20に結合する二重特異性抗原結合分子、並びにそれらの使用
JP7174009B2 (ja) Pd-1に対するヒト抗体
JP7783183B2 (ja) 自己免疫障害における抗bcma治療
JP7296363B2 (ja) 抗ctla-4抗体およびその使用
JP7792333B2 (ja) Bcmaおよびcd3に対する抗体を用いる処置方法
TW202115114A (zh) 針對靶向b細胞成熟抗原的多特異抗體之給藥方案及組合療法
CN108137700A (zh) 抗psma抗体、结合psma及cd3的双特异性抗原结合分子及其用途
WO2021092060A1 (en) Methods of treatment
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
US20230172923A1 (en) Methods of treating cytokine-related adverse events
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
CN121712524A (zh) 包含结合bcma和cd3的抗体的组合物以及治疗方法
WO2026033437A1 (en) Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
BR122025021892A2 (pt) Células hospedeiras